7:30 am Check In, Morning Coffee & Light Refreshments
8:20 am Chair’s Opening Remarks
Blockbuster ADCs Pushing the Boundary: Showcasing the ADCs Reshaping Standard of Care Oncology Treatments Into Wider Patient Populations
8:30 am Spotlighting Enhertu’s Historic HER2-Positive Solid Tumour Approval & Evaluating Performance to Expand to Ultralow Patient Populations
Synopsis
• Breaking down readouts from DESTINY clinical trials which led to tumour-agnostic HER2-positive solid tumour approval
• Outlining ongoing investigation of Enhertu in HER2 ultralow patient populations: what impact does target expression have across tumour types?
• Contextualising DB06 and other data to understand the reasons behind success and setbacks in ultra-low trials
9:00 am Accelerating Bioconjugate Development From Discovery to Commercialisation With WuXi XDC’s Fully Integrated Capabilities & Expanding Capacities
Synopsis
• Showcasing a one-stop discovery services platform to accelerate candidate selection, including mab/protein generation, payload linker synthesis, conjugate generation and in vitro, and in vivo characterisation
• Demonstrating fully integrated ADC CMC development with industry-leading DNA to IND timeline of 13-15 months; mAb/payload linker/conjugation DS & DP development and manufacturing all by in-house team and facilities
• Sharing insight into the rapidly expanding capacities for all ADC component manufacturing: to have five conjugations, four ADC DP facilities by mid-2026 in Wuxi city and Singapore, as well as a global network of mAb facilities and multiple linker-payload facilities
9:30 am Showcasing Phase II & III Readouts of Luvelta & Outlining Predications for Future ADC Innovation
Synopsis
• Sharing an update on clinical data for Luvelta targeting FRα in recurrent, platinum-resistant ovarian cancer, endometrial cancer, and AML
• Reflecting on the development and main drivers of successes in the ADC field
• Exploring future directions of the ADC field across dual payload conjugates, including Immune activating payload ADCs
10:00 am Morning Break & Networking
Synopsis
As the brightest minds of the ADC community unite all under one roof, use this valuable time to reconnect with your peers, meet fresh faces, and form long-lasting business “linkers” with a wide range of attendees before we split off into the five conference tracks.
Discovery
Chair: David Battersby, Team Leader, Associate Fellow, GSK
Download the Full Event Guide for full details
Evaluating Cutting-Edge Linker-Payload Design to Widen ADC Therapeutic Index
11.00 am Showcasing Next Generation Topoisomerase Inhibitor Linker-Payloads
• Highlighting a novel linker technology that improves resistance to
serum hydrolases
• Exploring linker-payload improved physicochemical properties of ADCs
• Utilising linker payload technology to improve the specificity of
tumour targeting
Max Lee, Associate Director, AstraZeneca
11.30 am Session Presented by
12.00 pm Tailored Linker-Payload Design for ADCs & SMDCs to Address Different Target Biologies
• Breaking down different payload profiles which match with ADC and SMDC design
• Addressing DMPK Challenges of Small Molecule Drug Conjugates (SMDCs)
• Reviewing translational aspects of ongoing ADC and SMDC programmes
Hans-Georg Lerchen, Chief Scientific Officer, Vincerx Pharma
12.30 pm Session Presented by
1.00 pm Lunch & Learn Sessions Presented by
ADC Target Showcase: Balancing Risk & Opportunity for Novel First-in-Class ADC Targets
2.00 pm Showcasing a Pan-Cancer ADC Targeting Oncofetal Chondroitin Sulfate
• Introducing oncofetal chondroitin sulfate (ofCS) as a novel anti-tumour target playing a key role in tumour immune evasion, cellular growth and cancer cell migration
• Presenting novel mAbs binding ofCS (Vartumabs) ADC, and in vivo demonstration of tumour penetration, induction of immunogenic cell death and a favourable toxicological profile
• Outlining ongoing Phase 0 PET imaging study with future clinical
potential for a safe and effective treatment for most cancers
Ali Salanti, Chief Executive Officer,VAR2 Pharmaceuticals
2.30 pm Showcasing IND-Stage Characterisation of ADCs Against a Novel Target
• Laying out the preclinical characterisation of ADCs with
established linker-payload against a novel target
• Breaking down novel target rationale against gastrointestinal tumours
• Looking ahead to clinical development for potential first and best-in-class ADC development
Dongzhou Jeffrey Liu, Chief Scientific Officer, Huadong Medicine
3.00 pm Session Provided by:
3:30 pm Afternoon Break & Networking
Establishing Confidence in the Clinic: Comprehensively Understanding ADC Clinical Performance to Maximise the Therapeutic Index
4:30 pm Our History to Serve the Innovators: A Step Ahead Against the Challenges of the Bioconjugates
Synopsis
• Discover the insides of a sustainable business model
• Learn about expertise, technology and integration of services
• Discuss capacity shortage challenges: what it means going forward
5:00 pm Correlating ADC Design Factors to Successful Efficacy & Safety Profiles in the Clinic
Synopsis
• Accurately characterising antibody, linker, payload, and overall conjugate contributions to ADC clinical performance
• Deep diving into ADC case studies to understand differentiated design impact on clinical safety and efficacy profiles
• Explaining favourable safety and efficacy profiles attributed to ADC designs against the same target or using different payloads
5:30 pm Demonstrating Technical Excellence in ADCs From Preclinical Development to Commercial Manufacturing
Synopsis
• Explore the integrated offer of mAb, drug-linker and conjugation expertise at Merck Life Science Services
• Overcome key challenges through simplified process and analytical platforms developed specifically for bioconjugates
• Experience right first-time delivery: seamless transfers from process understanding to GMP production
6:00 pm Assessing the Impact of ADC Design Philosophy Across Topoisomerase ADCs
Synopsis
• Breaking down the philosophy of novel ADC design and assessing validation from preclinical readouts
• Understanding the contribution of different design components towards ADC performance
• Forecasting validation of ADC philosophy impact in clinical trials
6:30 pm Chair’s Closing Remarks
6:30 pm Scientific Poster Session & Drinks Reception
Synopsis
This is a great opportunity to showcase your latest work and get face-to-face time with attending audience of ADC experts, as well as finding out insights from ongoing ADC development by your peers. In an informal setting, you will be able to discuss, debate, and display your work in the field while enjoying a drink of your choice at our dedicated drinks reception.